Over two decades, Medincell has built a proprietary technology platform, achieved its first FDA approval, and entered a new phase of growth driven by innovation, partnerships, and an expanding pipeline.
Our story
A proven technology platform A first commercial success with UZEDY® A growing portfolio of long-acting injectable therapies
2003
Incorporation
Medincell is founded with a clear ambition: to improve treatment adherence, expand access to innovative therapies and enhance patient outcomes worldwide.
2003 – 2013
Scientific foundations
Medincell’s research builds on the work of the CNRS laboratory led by Professor Michel Vert in Montpellier, France, leading to the first generation of BEPO® technology for the formulation and development of long-acting injectable therapies.
Early collaborations with pharmaceutical and veterinary companies help validate the technology’s potential.
2013
Strategic partnership with Teva
Medincell signs a licensing agreement with Teva to develop long-acting injectable antipsychotic treatments — a first major step toward global development.
2015
Building industrial capabilities
Medincell and Corbion create CM Biomaterials, a joint venture dedicated to manufacturing the polymers used in BEPO® formulations and strengthening related IP and know-how.
2016
First clinical milestone
First human injection of a BEPO®-based product. Core BEPO® patent granted in the United States
2017
Expanding the platform
Launch of an internal R&D portfolio designed to generate high-value data and support future partnerships First Global Health program initiated with the Gates Foundation in contraception BEPO® patent granted in Europe .
2018
Entering late-stage development
First Phase 3 clinical trial initiated for a BEPO® product, later approved as UZEDY®.
Successful IPO on Euronext Paris.
2019
A purpose-driven company
Medincell integrates its raison d’être into its bylaws, reinforcing its long-term commitment to innovation, access and patient impact.
2020
Global Health expansion
Launch of a second Global Health program, focused on malaria
2023
First FDA approval: from platform to product
FDA approval of UZEDY®, the first BEPO®-based treatment, for adults living with schizophrenia.
Commercial launch of UZEDY® in the United States by Teva, marking a decisive validation of Medincell’s technology platform and business model.
2024
A broader platform opportunity
Strategic partnership signed with AbbVie to develop a new generation of long-acting injectable therapies.
Medincell further strengthens its technology platform with BEPO® Star, designed to support the development of future programs.
2025
Growth confirmed
Second product, Olanzapine LAI, advances toward regulatory approval following positive Phase 3 results.
BEPO® Star patent granted in the United States.
2026
Scaling for the future
Regulatory submissions in the United States and Europe for Olanzapine LAI.
Pipeline reaches 15 partnered and internal programs at formulation stage.
Technology platform expansion supports a broader long-acting injectable portfolio across multiple indications.
A world-class team of 150 employees representing 25 nationalities supports Medincell’s global ambitions.
